Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2026. The document serves as a transaction notification regarding insider trading activity rather than a periodic financial report. GSK plc is a global biopharma company registered in England & Wales.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions by a Person Discharging Managerial Responsibilities (PDMR).
Material Changes and Transaction Details
The filing discloses two acquisitions of American Depositary Shares (ADS) by Diana Conrad, Chief People Officer, under the GSK pension plan on the New York Stock Exchange:
- Transaction 1: On March 24, 2026, 428.137 ADS were acquired at a price of $52.0278 per share.
- Transaction 2: On March 30, 2026, 12.186 ADS were acquired at a price of $54.4682 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains only a standard corporate description and transaction data.
Investor Verification Checklist
- Verify the total number of ADS held by Diana Conrad post-transaction to assess overall insider ownership levels.
- Confirm the specific terms of the GSK pension plan that facilitated these acquisitions.
- Review the company's most recent Form 20-F for comprehensive financial performance data, as this 6-K does not contain financial statements.